Development and optimization of a zein-coated inhalable HDAC inhibitor formulation as a potential treatment for idiopathic pulmonary fibrosis via three-fluid nozzle spray drying

Key Points

• The inhalable HDAC inhibitor formulation enhances bioavailability in lung tissues, potentially improving treatment outcomes.
• The optimized formulation achieved a particle size ideal for aerosol delivery, targeting effective deposition in the lungs.
• Using three-fluid nozzle spray drying, the method ensures a stable and effective inhalable product for therapeutic use.
• Significant progress may enable superior treatment options for idiopathic pulmonary fibrosis, with further clinical testing needed.